Project Grant R01CA303042
Award Date 6/23/26
Completion Date 5/31/31
Dollars Obligated $696K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- Federal Project Grant Award Summary The University of Tennessee Health Science Center received a $658,561 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 7, 2025, with a completion date of July 31, 2030. This award supports research focused on targeted MDM2 (Murine Double Minute 2) degradation as an improved therapeutic strategy for triple-negative breast cancer (TNBC). The project centers on optimization and...
- Federal Grant Award Summary Vanderbilt University received a $709,630 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026, through June 30, 2031. The award supports preclinical research to develop innovative combination therapies for Bacillus Calmette-Guerin (BCG)-refractory and recurrent non-muscle-invasive bladder cancer (NMIBC). The research involves developing intravesical gene delivery of the sodium/iodide...
- Federal Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects, received a $544,868 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026, through May 31, 2031. The award supports research investigating SLC13A3 and its role in tumor resistance to immunotherapy, with a focus on understanding how the itaconate-SLC13A3 metabolic axis suppresses major histocompatibility...
- Federal Grant Award Summary Emory University received a $602,847 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026, through June 30, 2031. The award supports research investigating the N-glycan modification pathway as a therapeutic target for triple-negative breast cancer (TNBC), particularly in BRCA1-deficient patient populations. The research focuses on understanding how the enzyme MAN1C1 (a glycosyl hydrolase)...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. a $398,544 Project Grant (CFDA 93.395: Cancer Treatment Research) effective April 8, 2026, through March 31, 2028, to conduct pre-clinical evaluation of PRT3789, a highly selective SMARCA2 degrader, for treating therapy-resistant triple-negative breast cancer (TNBC). The project addresses a critical clinical gap: patients with residual disease following neoadjuvant...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $648,626 to the University of California, Irvine, effective April 2, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically how programmed death receptor 1 (PD-1) blockade affects tumor microenvironments. The research seeks to...
- Federal Grant Award Summary The National Cancer Institute awarded a $671,252 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms of anti-tumor immunity mediated by immune cell triads. The research project, effective from July 1, 2026 through June 30, 2031, will advance fundamental understanding of how CD4 T cells, CD8 T cells, and dendritic cells must spatially organize and interact within tumors...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1.098 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on August 13, 2025, with a completion date of April 30, 2030. The funded research focuses on understanding the biological mechanisms controlling CD8+ tumor-infiltrating lymphocytes (TILs) and their progression through various functional states, including...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Van Andel Research Institute (VAI) a Project Grant totaling $112,234 under the Cancer Research Manpower program (CFDA 93.398) to conduct investigator-initiated cancer immunotherapy research from August 1, 2025, through July 31, 2027. The grant supports research targeting the PTGIR (prostacyclin receptor)-prostacyclin signaling pathway to overcome CD8 T cell exhaustion and enhance anti-tumor immunity. The project aims to...
- Federal Grant Award Summary New York University School of Medicine received a $695,852 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) awarded May 1, 2026, with completion scheduled for April 30, 2031. The research investigates T cell circuits within the lymphatic system during melanoma progression, specifically examining tumor-draining lymph nodes (TDLNs) as critical hubs for anti-tumor immune surveillance. The project focuses on...